With a median follow-up of 71 months, no difference in 5-year EFS (84% vs. 83%, P = 0.77) and LRC (96% vs. 97%, P = 0.91) was observed between patients receiving a radiotherapy boost and those without boost, respectively. Five-year OS, including salvage therapy, was excellent (boost vs. no boost: 97% vs. 95%, P = 0.58).
INTRODUCTION
Wilms tumour (WT) or nephroblastoma is the most common malignant tumour of the kidney in children, with 90% of cases occurring before the age of 7 years. 1, 2 The International Society of Paediatric Oncology (SIOP) in Europe and the National Wilms Tumour Study Group (NWTS), now Children's Oncology Group (COG), in the United States, have conducted different clinical trials on treatment optimisation for children with WT. While outcome for children with WT is highly successful across both groups, there is a difference in treatment philosophies. [2] [3] [4] [5] [6] [7] [8] In contrast to the COG approach that recommends primary surgery followed by adjuvant treatment, children treated within recent SIOP protocols receive upfront chemotherapy followed by surgery. Over the past decades, excellent outcome allowed efforts to reduce toxicity and burden of the treatment sustaining effectiveness. 5, 9 Stage and histology are considered to be the most important clinical prognostic factors so far. 2, 7, [10] [11] [12] Around 20% of all WT present as stage III, of which 30% is based on lymph node involvement, as assessed at time of surgery. Previous studies from SIOP and COG have shown that stage III WTs carry an increased risk of abdominal recurrence. 13, 14 Therefore, the radiotherapy boost dose in addition to flank irradiation (14.4 Gy + 10.8 Gy) has been common practice in such patients within previous SIOP protocols. [15] [16] [17] [18] [19] [20] [21] Over the past two decades a rising tendency occurred to omit the radiotherapy boost to the positive lymph nodes in order to avoid late sequelae. Whether the omission of radiotherapy boost impacts loco-regional control (LRC) and event-free survival (EFS) has, however, never been demonstrated.
The purpose of the current study is to evaluate the contribution of the radiotherapy boost dose in patients with stage III, intermediate- 39 ). 5 Treatment consisted of preoperative chemotherapy followed by nephrectomy with para-aortic lymph node sampling. Subsequently, the tumour was classified based on the revised SIOP working classification of renal tumours of the childhood, combining tumour staging system and histological risk classification. 12 Afterwards, patients were randomised to receive postoperative chemotherapy either with or without doxorubicin (Supplemental Fig. S1 ). Postoperative flank irradiation was recommended in children with stage III. Details of the protocol are available online (www.siop-rtsg.eu). Two hundred and fifty-one hospitals from 26 countries participated in this study. National and local regulatory and ethical approvals were obtained according to the national regulations.
PATIENTS AND METHODS

Study design
In the current analysis, only patients with intermediate-risk, stage III tumour, based on lymph node involvement (presence of vital or necrotic tumour cells after preoperative chemotherapy) were included. 12 
Systemic treatment
According to the SIOP protocol, all newly diagnosed patients with a local intra-renal tumour received preoperative chemotherapy (weekly iv vincristine (1.5 mg/m 2 ) combined with actinomycin-D (45 g/kg) every 2 weeks for 4 weeks), followed by an ipsilateral nephrectomy including standard lymph nodes sampling. Intermediate-risk, stage III WT patients received postoperative chemotherapy for 27 weeks (iv vincristine combined with actinomycin-D every 3 weeks and five additional doxorubicin doses, depending on the allocated randomisation) 5 (Supplemental Fig. S1 ). 
Radiotherapy
Statistical analysis
EFS (time to loco-regional or distant recurrence, or death from any cause), loco-regional disease control (time to loco-regional recurrence) and overall survival (time to death from any cause) were calculated from the date of diagnosis. Patients who were event free at the end of follow-up were censored at that time. For the current study, 5-year EFS, LRC and overall survival (OS) were used as endpoints. 
RESULTS
Patient characteristics
Between 
Stage III, positive lymph nodes only
Patient, tumour and treatment characteristics of the patient subset with stage III disease due to LN positive only, are listed in Table 1 . Information on radiotherapy was missing in eight patients (7% 
Disease control
With a median follow-up of 71 months (range 35-100) similar EFS was observed in patients receiving radiotherapy with boost and those without boost (P = 0.77) (Fig. 1A) . The 5-year EFS rate was 84% (95% CI 73-98%) for patients receiving radiotherapy with boost versus 83%
(95% CI 74-93%) for those without boost. Omission of the radiotherapy boost did not impact LRC (P = 0.91). The 5-year LRC rate was 96%
(95% CI 90-100%) for patients receiving radiotherapy with boost versus 97% (95% CI 92-100%) for those without boost (Fig. 1B) . Locoregional relapses occurred in 1 out of 36 (3%) patients who received the boost and 2 out of 65 (3%) patients without boost. Distant metastasis was the main reason for failure in patients undergoing radiotherapy (n = 11/101; 11%; Table 2 ). (Fig. 2) .
Survival
DISCUSSION
In SIOP-2001, radiotherapy to the flank and para-aortic lymph nodes followed by a boost dose of 10.8 Gy to the involved lymph node area was advised for all WT patients with stage III, intermediate-risk disease with positive or necrotic lymph nodes at the time of surgery. After a preliminary analysis in 2011, omission of the radiotherapy boost was pursued in a significant number of patients. 22 Our study suggests that such a postoperative radiotherapy dose reduction by omitting boost does not alter LRC and survival rates. at selected ages and doses. 30 Therefore, a reduction of the radiotherapy dose from 25.2 to 14.4 Gy by omission of the boost to the paraaortic lymph nodes may result in a significant benefit in ultimate sitting height. 30 Impaired creatinine clearance is observed in 19, 32 and 73% of patients after mean doses to the kidney of < 12, 12-24 and > 24 Gy, respectively. 26, 31, 32 After omission of the boost, it is expected that administration of a mean dose to the kidney above 12 Gy will become extremely rare. Aortic hypoplasia and renal artery stenosis after radiotherapy with dose ranges between 18-24 Gy (fractionated) and 10-12 Gy (single fraction intra-operative) have been identified in a limited number of patients. 33 Patients developed hypertension, middle aortic syndrome, mesenteric ischemia and critical aortic stenosis requiring bypass surgery.
In addition to a dose reduction by omission of the boost, innovative advanced radiotherapy techniques, such as image-guided intensitymodulated radiotherapy (IGRT) or pencil beam scanning proton therapy, have the potential for further reducing dose to the normal structures, especially the contralateral kidney, the pancreas and visceral fat, as well as the nipple area. Therefore, it merits prospective evaluation within the context of a clinical trial. 34 Unfortunately, the close anatomical relation of the target volume area to the musculoskeletal and vascular structures hinders sparing and further risk reduction.
Treatment-induced neoplasms constitute a well-recognised complication after therapy for WT. [35] [36] [37] The occurrence is related to the use of radiotherapy, the radiotherapy dose and the interaction of radiotherapy with doxorubicin. 36, 38, 39 After exclusion of basal cell carcinomas, Taylor et al. reported a 6.9% cumulative incidence of second primary neoplasms in the abdomen/pelvis region at 40 years posttreatment. 36 It is expected that the omission of the radiotherapy boost nostic factors biomarkers will be evaluated in the UMBRELLA study for future incorporation into risk stratification.
CONCLUSION
The results of this descriptive study demonstrate that omission of the 
